To the Editor: Hepatocellular carcinoma (HCC) is the third most lethal malignancy globally. Besides sorafenib, lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018. Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1 to 3, fibroblast growth factor receptors 1 to 4, platelet-derived growth factor receptor α, RET, and KIT. Patients who received lenvatinib experienced diarrhoea, and alopecia, and more instances of hypertension, proteinuria, and hypothyroidism. Here, we report two patients that developed irreversible pancreatic atrophy as a novel adverse event of lenvatinib.
The first patient received lenvatinib for 8 months at the recommended dose of 12 mg/day. Grade 1 diarrhea occurred 2 months post-treatment initiation of lenvatinib. Pancreatic exocrine insufficiency was diagnosed 3 months after the initiation of lenvatinib. Pancreatic-enzyme replacement was then performed to control diarrhea. We used volumetric measurement tools to calculate the pancreatic volume in a post-processing workstation (Advantage Workstation, version 4.6; GE Healthcare, Buc, France), revealing a 51% reduction in volume [Figure 1A and 1B]. A second patient received lenvatinib for 12 months at the recommended dose of 12 mg/day. To date, no diarrhea has occurred. Volumetric magnetic resonance imaging of the pancreas showed a 30% decrease in the volume [Figure 1C and 1D]. In summary, lenvatinib and sorafenib show the anti-angiogenic properties of anti-VEGF agents may reduce the microvasculature of normal tissues. Hescot et al first reported on two patients who developed irreversible pancreatic atrophy after prolonged treatment with sorafenib. Li et al also reported pancreatic atrophy could contribute to sorafenib-induced diarrhea. Patients frequently suffer from diarrhea, weight loss, anorexia, and nausea, considered common symptoms of exocrine pancreatic insufficiency. However, little is known about effects related to exposure to lenvatinib, and pancreatic atrophy amongst patients chronically treated with lenvatinib might be a predictive surrogate marker of therapeutic efficacy.
Declaration of patient consent
We certify that we have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
This work was supported by a grant from the Big Data Research and Development Project of the General Hospital of People's Liberation Army (No. 2018MBD-011).
Conflicts of interest
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136:359–386. doi: 10.1002/ijc.29210.
2. Tohyama O, Matsui J, Kodama K, Naoko H, Takayuki K, Kiyoshi O, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res
2014; 2014:638–747. doi: 10.1155/2014/638747.
3. Williams AJ, Chau W, Callaway MP, Dayan CM. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabet Med
2007; 24:35–40. doi: 10.1111/j.1464-5491.2007.02027.x.
4. Hescot S, Vignaux O, Goldwasser F. Pancreatic atrophyda new late toxic effect of sorafenib. N Engl J Med
2013; 369:1475–1476. doi: 10.1056/NEJMc1305302.
5. Xu L, Zhou DS, Zhao J, Spolverato G, Zhang YJ, Li SP, et al. Long-term therapy with sorafenib is associated with pancreatic atrophy (in Chinese). J Surg Res
2015; 199:314–321. doi: 10.1016/j.jss.2015.04.035.